Related Experiment Video

Updated: Jul 19, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma

Gulam Mustafa Hasan1, Md Imtaiyaz Hassan2, Sukhwinder Singh Sohal3

  • 1Department of Biochemistry, College of Medicine, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia.

ACS Omega
|August 7, 2023
PubMed

Insights

Phytochemicals and small molecules offer new avenues for non-small cell lung carcinoma (NSCLC) treatment by targeting key cellular signaling pathways. This review highlights compounds like EGCG and Gefitinib for their therapeutic potential in NSCLC management.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-small cell lung carcinoma (NSCLC) is a prevalent global cancer.
  • Phytochemicals and small molecule inhibitors are crucial in cancer prevention and treatment.
  • These agents interfere with critical cellular processes like proliferation, apoptosis, metastasis, and angiogenesis.

Purpose of the Study:

  • To review bioactive compounds and small molecule inhibitors for NSCLC therapy.
  • To elucidate their anticancer mechanisms and targeted signaling pathways.
  • To highlight specific therapeutic agents and their potential in NSCLC management.

Main Methods:

  • Literature review of phytochemicals and small molecule inhibitors.
  • Analysis of their effects on cellular signaling cascades (e.g., p53, NF-κB, STAT3, RAS, MAPK/ERK, Wnt, AKT/PI3K).
  • Focus on compounds like EGCG, Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein.

Main Results:

  • Identified various phytochemicals and small molecules with anticancer activity against NSCLC.
  • Demonstrated their ability to modulate key signaling pathways involved in cancer progression.
  • Highlighted specific compounds with significant therapeutic potential for NSCLC.

Conclusions:

  • Phytochemicals and small molecule inhibitors represent a promising therapeutic strategy for NSCLC.
  • Targeting specific cellular signaling pathways offers mechanistic insights for novel drug development.
  • Further research into these compounds can lead to improved NSCLC treatment outcomes.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
204